AR013139A1 - Analogos de hormonas glicoproteicas entrecruzados de disulfuro, uso de dichos analogos para preparar medicamentos, composicion farmaceutica, uso de dicha composicion para preparar medicamentos, y proceso para la preparacion de dichos analogos. - Google Patents

Analogos de hormonas glicoproteicas entrecruzados de disulfuro, uso de dichos analogos para preparar medicamentos, composicion farmaceutica, uso de dicha composicion para preparar medicamentos, y proceso para la preparacion de dichos analogos.

Info

Publication number
AR013139A1
AR013139A1 ARP980103091A ARP980103091A AR013139A1 AR 013139 A1 AR013139 A1 AR 013139A1 AR P980103091 A ARP980103091 A AR P980103091A AR P980103091 A ARP980103091 A AR P980103091A AR 013139 A1 AR013139 A1 AR 013139A1
Authority
AR
Argentina
Prior art keywords
analogs
hormone
cysteine
glycoprotein hormone
composition
Prior art date
Application number
ARP980103091A
Other languages
English (en)
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21967404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR013139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Serono Lab filed Critical Serono Lab
Publication of AR013139A1 publication Critical patent/AR013139A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un análogo de una hormona glicoproteica que está seleccionada del grupo que consiste de gonadotropina corionica (hCG), hormona luteinizante humana(hLH), hormona estimulante folicular humana (hFSH), hormona estimulante tiroide humana(hTSH ) y muteínas funcionales de las mismas, que tienen unasubunidad alfa y una subunidad beta, en donde las secuencia de aminoácidos de dichas subunidades de hormona glicoproteica son modificadas de manera decrear un enlace de disulfuro deintersubu nidad entre una cisteína de la subunidad alfa, y una cisteína de subunidad beta, cuyas cisteínas estándispuestas dentro de dos residuos de posiciones de residuos de cisteína natural de dicha hormona glicoproteica, y no fuera de lasunidades d e cisteína másexternas de la unidad natural correspondiente, para estabilidad perfeccionada, dicho análogo retiene por lo menos 25% de la afinidad de dicha hormonaglicoproteica para su receptor de hormona glicoproteica natural,composicion farmac éutica, uso de dicha composicion para preparar un medicamento parael tratamiento de la infertilidad y para limitar la fertilidad, molécula de ADN recombinante, célula huésped eucariotica transformada con dicha molécula,yproceso para la preparaci on de dicho análogo.
ARP980103091A 1997-06-25 1998-06-26 Analogos de hormonas glicoproteicas entrecruzados de disulfuro, uso de dichos analogos para preparar medicamentos, composicion farmaceutica, uso de dicha composicion para preparar medicamentos, y proceso para la preparacion de dichos analogos. AR013139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5078497P 1997-06-25 1997-06-25

Publications (1)

Publication Number Publication Date
AR013139A1 true AR013139A1 (es) 2000-12-13

Family

ID=21967404

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103091A AR013139A1 (es) 1997-06-25 1998-06-26 Analogos de hormonas glicoproteicas entrecruzados de disulfuro, uso de dichos analogos para preparar medicamentos, composicion farmaceutica, uso de dicha composicion para preparar medicamentos, y proceso para la preparacion de dichos analogos.

Country Status (21)

Country Link
US (1) US8530190B1 (es)
EP (2) EP1775346B1 (es)
JP (3) JP3950484B2 (es)
KR (2) KR100706469B1 (es)
CN (3) CN100404551C (es)
AR (1) AR013139A1 (es)
AT (2) ATE335000T1 (es)
AU (1) AU747179B2 (es)
BR (1) BR9810478A (es)
CA (1) CA2293731C (es)
CY (2) CY1105763T1 (es)
DE (2) DE69835433T2 (es)
DK (2) DK1775346T3 (es)
ES (2) ES2268781T3 (es)
HK (1) HK1033149A1 (es)
HU (1) HU227908B1 (es)
IL (2) IL133686A0 (es)
PT (2) PT996629E (es)
SI (2) SI1775346T1 (es)
WO (1) WO1998058957A2 (es)
ZA (1) ZA985545B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716428B1 (en) * 1999-10-06 2004-04-06 The Ohio State University Research Foundation Antigenic modification of polypeptides
UA78676C2 (en) * 2000-02-22 2007-04-25 Applied Research Systems Purified lh
AU2000280019A1 (en) * 2000-10-06 2002-04-22 Regeneron Pharmaceuticals, Inc. Polypeptides, methods of making, and uses thereof
JP2005509652A (ja) * 2001-11-08 2005-04-14 モイル，ウィリアム，アール 蛋白質の瘤
EP1951395B1 (en) 2005-09-14 2012-02-29 Ares Trading S.A. Method for the quantitative determination of poloxamers
RS51792B (en) * 2006-01-17 2011-12-31 Merck Serono Sa. NEW FSH WITH GLYCOSILATION OPTION D3N
CN101250531B (zh) * 2006-11-27 2013-04-24 株式会社Lg生命科学 一核苷酸序列、包含该序列的表达载体、该载体转化的动物细胞及利用该细胞生产人fsh的方法
DE202009009905U1 (de) 2008-02-08 2009-10-29 Biogenerix Ag Flüssig-Formulierung von FSH
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
AU2010207725B2 (en) * 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
UA106369C2 (ru) 2009-04-01 2014-08-26 Рациофарм Гмбх Способ очистки рекомбинантного фсг
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
WO2012131306A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
RS58881B1 (sr) * 2012-07-30 2019-08-30 Trophogen Inc Dugodelujući superagonisti glikoproteinskih hormona
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
US20230365944A1 (en) * 2020-09-30 2023-11-16 The University Of North Carolina At Chapel Hill Engineered stable lactate oxidoreductases, compositions, devices, kits and uses thereof
WO2022150878A1 (en) * 2021-01-13 2022-07-21 University Of Newcastle Compositions and methods of using targeting peptides and nanopharmaceuticals for the sterilization of cats and dogs
WO2024099445A1 (zh) * 2022-11-10 2024-05-16 康立泰生物医药(青岛)有限公司 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079230A (en) * 1988-09-12 1992-01-07 Pitman-Moore, Inc. Stable bioactive somatotropins
US5691455A (en) * 1995-10-24 1997-11-25 Akzo Nobel N.V. Gonadotropins with non-native disulfide bridges
US20090209453A1 (en) * 2005-04-13 2009-08-20 University Of Medicine And Dentistry Of New Jersey Glycoprotein Hormone Analogs

Also Published As

Publication number Publication date
ATE335000T1 (de) 2006-08-15
CN1548458A (zh) 2004-11-24
ES2268781T3 (es) 2007-03-16
WO1998058957A3 (en) 1999-04-22
KR100706469B1 (ko) 2007-04-10
AU7986198A (en) 1999-01-04
SI1775346T1 (sl) 2009-10-31
EP1775346A1 (en) 2007-04-18
KR20040039421A (ko) 2004-05-10
JP4278668B2 (ja) 2009-06-17
EP0996629A2 (en) 2000-05-03
US8530190B1 (en) 2013-09-10
JP2005162734A (ja) 2005-06-23
WO1998058957A2 (en) 1998-12-30
DE69835433T2 (de) 2007-03-08
CN1197968C (zh) 2005-04-20
CN1302010C (zh) 2007-02-28
IL133686A (en) 2007-07-24
EP0996629B1 (en) 2006-08-02
HUP0100681A1 (hu) 2001-06-28
SI0996629T1 (sl) 2006-12-31
JP4279768B2 (ja) 2009-06-17
ATE439439T1 (de) 2009-08-15
HUP0100681A3 (en) 2004-03-01
CY1105763T1 (el) 2011-02-02
IL133686A0 (en) 2001-04-30
JP3950484B2 (ja) 2007-08-01
CA2293731C (en) 2010-01-12
KR100560279B1 (ko) 2006-03-10
ZA985545B (en) 1999-04-01
HU227908B1 (en) 2012-05-29
CN1269833A (zh) 2000-10-11
DK0996629T3 (da) 2006-12-04
PT996629E (pt) 2006-12-29
HK1033149A1 (en) 2001-08-17
DE69841063D1 (de) 2009-09-24
JP2001521402A (ja) 2001-11-06
DK1775346T3 (da) 2009-09-28
ES2332931T3 (es) 2010-02-15
DE69835433D1 (de) 2006-09-14
AU747179B2 (en) 2002-05-09
CN100404551C (zh) 2008-07-23
KR20020006720A (ko) 2002-01-26
CY1109439T1 (el) 2014-08-13
PT1775346E (pt) 2009-08-25
WO1998058957A9 (en) 1999-06-03
JP2007016040A (ja) 2007-01-25
BR9810478A (pt) 2000-09-12
EP1775346B1 (en) 2009-08-12
CA2293731A1 (en) 1998-12-30
CN1548459A (zh) 2004-11-24

Similar Documents

Publication Publication Date Title
AR013139A1 (es) Analogos de hormonas glicoproteicas entrecruzados de disulfuro, uso de dichos analogos para preparar medicamentos, composicion farmaceutica, uso de dicha composicion para preparar medicamentos, y proceso para la preparacion de dichos analogos.
Practice Committee of the American Society for Reproductive Medicine Gonadotropin preparations: past, present, and future perspectives
Habibi et al. Functional relationship between receptor binding and biological activity for analogs of mammalian and salmon gonadotropin-releasing hormones in the pituitary of goldfish (Carasslus auratus)
Millar et al. Chimeric Analogues of Vertebrate Gonadotropin-Releasing Hormones Comprising Substitutions of the Variant Amino Acids in Positions 5, 7, and 8: Characterization of requirements for receptor binding and gonadotropin release in mammalian and avian pituitary gonadotropes
KR890701626A (ko) 뇨난포 자극호르몬
JPH06504794A (ja) 新規アミリン作動薬ペプチドおよびその使用
RU2015122887A (ru) КОМПОЗИЦИИ И СПОСОБЫ ПОВЫШЕНИЯ РЕПРОДУКТИВНОЙ АКТИВНОСТИ У МЛЕКОПИТАЮЩИХ, НЕ ЯВЛЯЮЩИХСЯ ЧЕЛОВЕКОМ, С ПРИМЕНЕНИЕМ БИОЛОГИЧЕСКИ АКТИВНОГО РЕКОМБИНАНТНОГО ФОЛЛИКУЛОСТИМУЛИРУЮЩЕГО ГОРМОНА (rFSH)
Ludwig et al. Ovarian stimulation: from basic science to clinical application
CY1107666T1 (el) Διαδικασια για την παρασκευη συνθεσεων γοναδοτροπινης
KR960704041A (ko) 사람 인터루킨-10의 효능제 및 길항제(Agonists and antagonists of human interleukin-10)
EP1641824B1 (en) Relaxin superfamily peptide analogues
Liu et al. The purification and chemistry of pituitary glycoprotein hormones
AR035077A1 (es) Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos
PT1261622E (pt) Lh purificada
ES2543198T3 (es) Mutantes de FSH
JP2009523445A (ja) 新規ｆｓｈグリコシル化変異体ｄ３ｎ
JPH01502662A (ja) たん白
BOUSFIELD et al. Effects of removal of carboxy-terminal extension from equine luteinizing hormone (LH) β-subunit on LH and follicle-stimulating hormone receptor-binding activities and LH steroidogenic activity in rat testicular Leydig cells
Papanikolaou et al. Emerging drugs in assisted reproduction
KR900702048A (ko) 고나도트로핀 및 그에 의한 과할성 작용제의 제조 방법
Gordon New developments in gonadotrophin pharmacology
JPS63316799A (ja) 副甲状腺ホルモン拮抗剤の二量体
Chopineau et al. Evidence that the alpha-subunit influences the specificity of receptor binding of the equine gonadotrophins
REICHERT JR Further studies on species differences in follicle stimulating hormone as revealed by the slope in the Steelman-Pohley assay
Aggarwal et al. Effect of the alpha subunit of equine LH on the FSH induced cAMP production in rat seminiferous tubule cells

Legal Events

Date Code Title Description
FG Grant, registration